US009511130B2

(12) **United States Patent**
Serino et al.

(10) **Patent No.: US 9,511,130 B2**
(45) **Date of Patent: Dec. 6, 2016**

(54) ***ESCHERICHIA COLI* VACCINE COMBINATION**

(75) Inventors: **Laura Serino**, Siena (IT); **Mariagrazia Pizza**, Siena (IT)

(73) Assignee: **GlaxoSmithKline Biologicals SA**, Rixensart (BE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 34 days.

(21) Appl. No.: **14/344,892**

(22) PCT Filed: **Sep. 14, 2012**

(86) PCT No.: **PCT/IB2012/054825**

§ 371 (c)(1),
(2), (4) Date: **Nov. 10, 2014**

(87) PCT Pub. No.: **WO2013/038385**

PCT Pub. Date: **Mar. 21, 2013**

(65) **Prior Publication Data**

US 2015/0118261 A1 Apr. 30, 2015

(30) **Foreign Application Priority Data**

Sep. 14, 2011 (GB) 1115906.8
Jul. 25, 2012 (GB) 1213251.0

(51) **Int. Cl.**
A61K 39/108 (2006.01)
C07K 14/245 (2006.01)
A61K 39/00 (2006.01)

(52) **U.S. Cl.**
CPC ***A61K 39/0258*** (2013.01); ***C07K 14/245*** (2013.01); *A61K 2039/54* (2013.01); *A61K 2039/541* (2013.01); *A61K 2039/542* (2013.01); *A61K 2039/543* (2013.01); *A61K 2039/55516* (2013.01); *A61K 2039/55544* (2013.01)

(58) **Field of Classification Search**
CPC A61K 39/0258; A61K 2039/54; A61K 2039/55544; A61K 2039/542; A61K 2039/543; A61K 2039/55516; A61K 2039/541; C07K 14/245
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,057,540	A	10/1991	Kensil et al.
5,916,588	A	6/1999	Popescu et al.
6,090,406	A	7/2000	Popescu et al.
6,207,646	B1	3/2001	Krieg et al.
6,239,116	B1	5/2001	Krieg et al.
6,429,199	B1	8/2002	Krieg et al.

FOREIGN PATENT DOCUMENTS

EP	0626169	A2	11/1994
EP	0735898	A1	10/1996
EP	0761231	A1	3/1997
EP	0835318	A2	4/1998
WO	90/14837	A1	12/1990
WO	94/00153	A1	1/1994
WO	98/40100	A1	9/1998
WO	98/57659	A1	12/1998
WO	99/11241	A1	3/1999
WO	99/27960	A1	6/1999
WO	99/40936	A2	8/1999
WO	99/44636	A2	9/1999
WO	99/52549	A1	10/1999
WO	02/081653	A2	10/2002
WO	03/024480	A2	3/2003
WO	03/024481	A2	3/2003
WO	2005/103073	A2	11/2005
WO	2006/089264	A2	8/2006
WO	2006/091517	A2	8/2006
WO	2009/104092	A2	8/2009
WO	2011/004263	A2	1/2011
WO	2011/007257	A1	1/2011
WO	2011/080595	A2	7/2011

OTHER PUBLICATIONS

Search Report received for Great Britain Patent Application No. 1115906.8, mailed on Jan. 11, 2012, 2 pages.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/IB2012/054825, mailed on Mar. 27, 2014, 13 pages.
International Search Report and Written Opinion received for PCT Patent Application No. PCT/IB2012/054825, mailed on Apr. 5, 2013, 18 pages.
Andrianov et al., "Preparation of Hydrogel Microspheres by Coacervation of Aqueous Polyphosphazene Solutions", Biomaterials, vol. 19, No. 1-3, Jan. 1998, pp. 109-115.
Andrianov at al., "Protein Release from Polyphosphazene Matrices", Advanced Drug Delivery Reviews, vol. 31, No. 3, May 1998, pp. 185-196.
Beignon et al., "The LTR72 Mutant of Heat-Labile Enterotoxin of *Escherichia coli* Enhances the Ability of Peptide Antigens to Elicit CD4+ T Cells and Secrete Gamma Interferon after Coapplication onto Bare Skin", Infection and Immunity, vol. 70, No. 6, Jun. 2002, pp. 3012-3019.
Durant et al., "Identification of Candidates for a Subunit Vaccine against Extraintestinal Pathogenic *Escherichia coli*", Infection and Immunity. vol. 75, No. 4, Apr. 2007, pp. 1916-1925.
Evans et al., "Enhancement of Antigen-Specific immunity via the TLR4 Ligands MPL™ Adjuvant and Ribi.529", Expert Review of Vaccines, vol. 2, No. 2, Apr. 2003, pp. 219-229.
Gerber et al., "Human Papillomavirus Virus-Like Particles are Efficient Oral Immunogens when Coadministered with *Escherichia coli* Heat-Labiie Enterotoxin Mutant R192G or CpG DNA", Journal of Virology, vol. 75, No. 10, May 2001, pp. 4752-4760.
Glück et al., "New Technology Platforms in the Development of Vaccines for the Future", Vaccine, vol. 20, Suppl. 5, Dec. 20, 2002, pp. B10-B16.

(Continued)

Primary Examiner — Padma V Baskar
(74) *Attorney, Agent, or Firm* — Morrison & Foerster LLP

(57) **ABSTRACT**

The invention provides an immunogenic composition comprising a combination of (i) bacterial Ig-like domain protein fragment (orf405B) having the amino acid sequence set forth in SEQ ID NO:2 or a protein having at least 80% similarity thereto, and (ii) putative Lipoprotein (orf3526) having the amino acid sequence set forth in SEQ ID NO:8 or a protein having at least 80% similarity thereto.

7 Claims, 15 Drawing Sheets